Pipeline
| Product Candidate | Indication | Preclinical | Early-Stage Clinical | Late-Stage Clinical |
|---|---|---|---|---|
Nana-val (nanatinostat + valganciclovir) |
Relapsed/Refractory EBV+ Lymphoma | |||
Nana-val |
Recurrent/Metastatic EBV+ Solid Tumors | |||
Vecabrutinib BTK/ITK inhibitor, in combination w/ CAR T-cell therapy |
I-O Combinations Multiple Undisclosed | |||
VRx-510* PDK-1 inhibitor |
Oncology Multiple Undisclosed | |||
Other HDACi Combinations |
HPV+ cancers I-O Combinations Multiple Undisclosed | |||
| Product Candidate | Indication | Stage |
|---|---|---|
| Nana-val (nanatinostat + valganciclovir) | Relapsed/Refractory EBV+ Lymphoma | Late-Stage Clinical |
| Nana-val | Recurrent/Metastatic EBV+ Solid Tumors | Early-Stage Clinical |
| Vecabrutinib BTK/ITK inhibitor, in combination w/ CAR T-cell therapy | I-O Combinations Multiple Undisclosed | Early-Stage Clinical |
| VRx-510* PDK-1 inhibitor | Oncology Multiple Undisclosed |
Preclinical |
| Other HDACi Combinations | HPV+ cancers I-O Combinations Multiple Undisclosed |
Preclinical |
EBV+: Epstein-Barr Virus Positive; I-O: Immuno-oncology; HPV: Human papillomavirus; *formerly SNS-510
Regulatory Status
The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for nanatinostat in combination with valganciclovir for the treatment of relapsed/refractory Epstein-Barr virus (EBV)-positive lymphoid malignancies.
- Orphan Drug Designations granted for nanatinostat with valganciclovir for the treatment of:
- T-cell lymphoma
- Post-transplant lymphoproliferative disorder (PTLD)
- Plasmablastic lymphoma
- EBV+ Diffuse large B-cell lymphoma, not otherwise specified (EBV+ DLBCL, NOS)
Viracta is enrolling patients in clinical trials to treat Relapsed/Refractory EBV+ lymphomas as well as Recurrent/Metastatic EBV+ solid tumors. For more information about these studies, see ClinicalTrials.gov.
Contact: clinicaltrials@viracta.com
Viracta has an Expanded Access Policy in compliance with the 21st Century Cures Act.
